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 Since early in evolutionary history, alternative RNA splicing has been an important 
method for metazoan organisms to regulate gene expression, allowing for a vastly expanded 
proteome without the need for significant genome expansion.  By tightly regulating the inclusion 
and exclusion of parts of genes using cis-acting elements and trans-acting factors, the splicing 
machinery can create specific isoforms of proteins in response to changes in developmental time, 
spatiotemporal or environmental factors, etc.  Recently, misregulation of this system has been 
discovered increasingly in various disease states, including many (if not most) cancers.  
Significantly, aberrant alternative RNA splicing has been implicated in the acquisition of 
chemotherapy resistance to certain drugs, including cisplatin.  Understanding how the splicing 
machinery fails to act properly in cancer will be important for creating novel gene-based 
therapies in the future.  In this study, I aimed to understand how an important splicing factor 
implicated in the regulation of cancer-related transcripts, hnRNP H, causes changes in alternative 
splicing in its own mRNA and of other genes.  It was shown that cisplatin causes a dose-
dependent decrease in two paralagous exons, HNRNPH1 Exon 4 and HNRNPH3 Exon 3.  
Structurally similar control compounds did not cause such changes, implying that the effect is 
specific to cisplatin-induced genotoxic stress.  Gel shift assays confirmed the interaction of 
hnRNP H with its own mRNA in these autoregulatory exons, implying a pathway that allows 
cancer cells to modulate the levels of this important protein factor.  
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1.0  INTRODUCTION 
The splicing of pre-mRNA to a mature mRNA transcript is a tightly regulated process 
directed by the spliceosome in eukaryotic organisms.  Acting through two subsequent trans-
esterification reactions, intronic sequences are removed and exonic sequences are spliced 
together.  A number of RNA elements and protein factors are responsible for alternative splicing 
via exon/intron definition, spliceosome assembly, and complex remodeling of snRNPs, 
enhancing or inhibiting the splicing machinery from continuing.  The intricate regulatory 
networks controlling alternative RNA splicing allow for finely tuned and temporally dynamic 
reactions to developmental stages, environmental cues, and cell-type dependent processes. 
1.1 THE BASICS OF RNA SPLICING: CANONICAL ELEMENTS AND THE 
SPLICING MACHINERY 
While alternative splicing provides cells a significant level of flexibility for gene 
expression through a complex series of molecular interactions and subsequent decisions, the 
principles underlying the splicing reaction itself in addition to constitutive splicing also provide 
insight into how this regulation occurs.  Numerous protein and RNA factors are involved, some 
of which are required to demark the location of intron and exon boundaries on the pre-mRNA, 
while others are important for aligning these regions properly to allow accurate cutting and 
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reattaching of the intron-exon borders.  While these components are necessary for constitutive 
splicing, they are also involved in alternative splicing decisions, along with many other 
important regulators (discussed later).  The three main constituents of the splicing reaction are 
the RNA sequences used to guide the other molecules, the RNA-protein complexes – snRNPs – 
used to recognize them, and the remainder of the macromolecular machinery used to perform the 
splicing reaction itself, the spliceosome. 
1.1.1 Cis-acting Elements Define Introns and Exons 
In order to be processed properly, intron-exon boundaries on pre-mRNA must be recognized by 
the splicing machinery at the appropriate positions.  The most important sequences for this 
recognition are the 5’ splice site, the 3’ splice site, and the branch point.  In humans, the 
canonical 5’ splice site consensus sequence is CAGguragu (R = purine), whereby the capital 
letters are the final nucleotides of the exon and the lowercase letters represent the beginning of 
the intron (Mount 1982).  The 3’ splice site consists of the final bases of the intron, usually AG, 
the upstream polypyrimidine tract, and the branch point, whose consensus sequence is 
YNYURAC and contains the catalytically activated adenosine residue essential for splicing 
chemistry (Zhuang et al.1989; Lin and Patton 1995).  The splicing reaction itself is a series of 
two trans-esterification reactions: in the first step, the 2’-OH of the activated branch point 
adenosine performs a nucleophilic attack on the 5’ splice site of the upstream exon, creating a 5’-
2’ bond.  While held in place by RNA-protein interactions, the free 3’-OH of the 5’ splice site 
attacks the 3’ splice site, releasing the intronic lariat and the newly spliced RNA.   
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1.1.2 Cis-elements are Recognized by snRNPs 
While intronic and exonic sequences are often displayed as distinct units, actual mRNA has no 
such means by which to differentiate sequences to include and sequences to exclude from the 
final transcript (Wang and Burge 2008).  Therefore, the splicing machinery must decode which 
regions are to be included and excluded from sequence data.  This is accomplished through a 
series of well-defined RNA-protein interactions via complexes called snRNPs (small nuclear 
ribonucleoproteins), associations of small nuclear RNAs (snRNAs) and their associated proteins 
(e.g., Sm proteins, U2AF, etc.).  Because nucleic acids readily base pair in a sequence-specific 
manner, snRNAs are used to identify the consensus sequences discussed above (i.e., 5’ splice 
site, 3’ splice site, and branch point).  The major-type snRNPs are U1, U2, U4, U5, and U6, each 
of which recognize a specific region of pre-mRNA or stabilize intermediates in the splicing 
reaction.  The complementarity of pre-mRNAs to snRNAs can partially predict how well an 
exon will be recognized by the splicing machinery, though several other factors contribute to the 
“strength” of an exon. 
1.1.3 The Spliceosome 
While each snRNP has a defined role in properly splicing pre-mRNA to mature mRNA, 
the process is stepwise and thus requires the formation of a macromolecular machine known as 
the spliceosome.  With the help of the spliceosome, pre-mRNA can proceed through several 
complexes of snRNPs and associated factors that allow proper intron and exon recognition. The 
reaction begins with the H complex, which is composed of an assortment of randomly and 
nonspecifically binding RNA-binding proteins.  Next, U1 binds to the 5’ splice site, followed by 
 3 
U2 binding the branch point in a conformation that allows adenosine to become catalytically 
active.  Next, the U4/5/6 tri-snRNP binds, causing the release of U1 and U4 snRNPs.  After this 
release, U6 replaces U1 but simultaneously binds U2 snRNP.  This brings the 5’ splice site and 
branch point sequence in close physical proximity.  Finally, the C complex, or catalytically 
active complex, allows the 2’-OH of the branch point adenosine to attack the 5’ splice site.  This 
newly freed upstream RNA molecule is held in place by U5, which allows the second trans-
esterification reaction to take place.  Following this, the lariat and newly spliced RNAs are 
released and snRNPs are recycled.  This series of molecular exchanges and rearrangements is 
known as the spliceosome cycle, and it can be used to explain how mutations in snRNPs can 
have deleterious effects for global splicing (Elliott and Ladomery 2011, Chapter 6, Refs. 19, 23-
40). 
1.2 ALTERNATIVE SPLICING, THE SPLICING CODE, AND DECISION-MAKING 
In order to create the proteomic diversity observed in metazoan organisms from the 
number of genes contained in the genome, several transcripts must be available to cells when 
creating mature mRNA from immature mRNA from a majority of genes.  Therefore, decisions 
regarding which portions of nascent transcripts to exclude and include must be made utilizing the 
splicing machinery described above in addition to several other layers of regulation through a 
pathway known as alternative RNA splicing.  The integration of these signals based on mRNA 
sequence and interacting proteins is collectively referred to as the “splicing code”.   
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1.2.1 Cis-acting Motifs: ESSs, ISS, ESEs, ISEs 
The ability of the spliceosome to decode what is supposed to be an exon versus what is 
supposed to be an intron in any given environment is dependent upon its recognition of 
regulatory sequences on the RNA molecule itself.  While the consensus sequences discussed 
above for the 3’ and 5’ splice sites and branch point sequence are crucial for exon and intron 
definition, other motifs play important roles in aiding or hindering the assembly of the 
spliceosome.  These sequences can be categorized into four types of binding sites: Exonic 
Splicing Silencers (ESSs), Intronic Splicing Silencers (ISSs), Exonic Splicing Enhancers (ESEs), 
and Intronic Splicing Enhancers (ISEs).  Splicing enhancers tend to favor the inclusion of an 
exon into a final transcript, whereas silencers tend to inhibit exonic inclusion.  Constitutively 
included and strong alternatively included exons tend to either contain several ESEs, few ESSs, 
or both.  Likewise, weak exons and pseudoexons contain many splicing silencers and few 
enhancers.  The consensus sequences for these sites vary extensively, and can even overlap with 
each other.   
1.2.2 Trans-acting Factors: Diverse Roles of hnRNPs and SR Proteins 
The cis-acting motifs discussed above are recognized by RNA-binding proteins known as 
splicing factors. While the structural diversity of these proteins is high, the most common 
domain conserved amongst them is the RNA-recognition motif, or the RRM.  These proteins can 
be divided into two major categories: hnRNPs and SR proteins.   
SR proteins all share an RS domain, rich in arginine and serine residues, and often 
contain one or more RRMs (Graveley 2000; Maniatis and Tasic 2002).  The SR domain 
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stabilizes binding to mRNA while also facilitating protein-protein interactions for regulatory 
purposes.  SR proteins are typically considered to be splicing enhancers, blocking repressors 
from binding or stabilizing components of the spliceosome, either directly or through 
cooperative interactions across snRNPs.  Phosphorylation of SR proteins often acts as a way to 
activate their splicing activity, while dephosphorylation often shuttles them to the cytoplasm 
(Stamm 2007).  This added level of regulation allows continuous coupling of environmental cues 
to levels of SR proteins in the nucleus, titrating binding to nascent mRNA (Long and Ceceres 
2009). 
The other major type of splicing factor, hnRNPs, are some of the most abundant proteins 
in the cell, and mammals can have up to 25 different types (Choi et al. 1986; Dreyfuss 1993; 
Ladd and Cooper 2002).  With a few notable exceptions (such as hnRNP K and hnRNP E), 
hnRNPs contain at least one RRM or quasi-RRM (qRRM) and often a protein interaction domain 
that allows regulation and localization similar to SR proteins.  hnRNPs are often thought to be 
splicing silencers, and can act through one of several methods: direct competition, by which 
spliceosomal components are physically blocked from binding their RNA motifs; 
oligomerization and “coating” of an exon to prevent recognition by spliceosomal components; 
dimerization across RNA molecules, causing looping out of regions to make them invisible to 
the spliceosome; and preventing interactions between spliceosomal components across an exon 
during exon definition. 
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1.3 STRESS AND ALTERNATIVE SPLICING 
As discussed previously, alternative splicing is an efficient means for cells to couple 
environmental factors to regulation of gene expression.  Therefore, one may expect alternative 
RNA splicing to be involved at least partially in the cellular response to environmental stressors.  
Additionally, these pathways are often misregulated in cancer, so the combined effects of stress 
on splicing and cancer on splicing must be considered.  For example, DNA damage response 
pathways tend to shut down RNA production while chromosomal lesions are fixed, whereas 
highly replicative cancers tend to speed up RNA production (Lenzken 2013).  This may be 
significant because modifying concentrations of splicing factors being produced may alter 
alternative splicing events on a global scale.  Likewise, overproducing splicing factors, as is 
often the case in cancers, could shift splicing events in a different direction.  Genotoxic damage, 
such as cisplatin-induced damage, can indirectly shift alternative splicing patterns by inhibiting 
transcription.  Because splicing is often cotranscriptional, processing of nascent mRNA separate 
from transcription may produce different splice isoforms.  In each of these ways and likely 
others, chemical stress brought about by chemotherapeutic agents and/or tumorigenic stress 
likely have long-range effects on splicing, which may directly or indirectly alter the cell’s ability 
to correct genetic/genomic lesions.  Interestingly, Hai and colleagues reported that a specific cis-
acting motif, the G-tract (bound by hnRNP H), modulates splicing patterns in response to 
apoptotic-inducing agents.  Though this example is highly specific, it is reasonable to believe 
other motifs work similarly using similar compounds (Hai 2008).   
 The cotranscriptional nature of splicing can also link stress to splicing via RNA 
polymerase II elongation.  For example, UV irradiation of cells leads to hyperphosphorylation of 
the RNA pol II CTD, leading to downregulation of elongation activity.  Muñoz and colleagues 
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demonstrated that this hyperphosphorylation caused the same alternative splicing effects as UV 
irradiation in a p53-independent pathway, showing that the alternative splicing response to stress 
may be linked to physical DNA damage (Muñoz et al. 2009).  Similarly, stress-inducing 
compounds like DRB which slow transcription elongation cause shifts in alternative splicing, 
though this likely has more to do with regulation of the RNA pol II complex in factors like P-
TEFb and CDK9 rather than insults to genomic DNA (Muñoz et al. 2010).   
Beyond these factors, it is believed that combinatorial control of splicing factors and 
other regulators, often alternatively spliced themselves, lead to many shifts in response to stress.  
In light of this, MDM2, an important gene involved in the regulation of p53, has been shown to 
respond to stressors through alternative splicing shifts in cis-regulated intronic elements, though 
the upstream regulators of this effect have not been identified (Singh et al. 2009).  Though this is 
only one example of a gene responding to stress through specific RNA elements, it is likely that 
many others act in similar ways.  Additionally, the regulatory pathways leading to these changes 
are largely mysterious and require further study.  High-throughput technologies and systems 
biology will no doubt be of great use in these experiments, and will contribute greatly to our 
understanding of global alternative splicing regulation in response to environmental cues. 
1.4 HNRNP H 
Heterogeneous nuclear ribonucleoprotein H is a member of the ubiquitously expressed 
hnRNP F/H family of splicing factors (Bent 1995).  It binds RNA via three quasi-RRMs (qRRM) 
and can interact with several other splicing factors (UniProt Consortium 2013).  hnRNP H binds 
G-rich elements when interacting with pre-mRNA, and can act as both a splicing silencer and 
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enhancer depending on the context (Dominguez 2006).  G-rich elements were recently 
implicated in special importance for cancer-regulated genes, and hnRNP H has indeed been 
shown to regulate the mRNA of several genes important for the formation/progression of cancer 
and cell survival, such as Bcl-x and p53 (Sohail 2014; Garneau 2005; Rauch 2010; LeFave 2011; 
Decorsière 2011).  It is of special note that hnRNP H’s interaction with p53 is not one of splicing 
regulation, but of 3’ end stabilization in response to stress.  This reinforces the idea that hnRNPs 
and other RNA binding proteins do not always have singular roles, and that post-transcriptional 
modifications of these molecules (such as splicing or mRNA degradation via nonsense mediated 
decay) can have downstream effects on other effectors of the proteins (Goldstrohm et al. 2001). 
1.5 THESIS AIMS 
In light of the information presented above, we aim to find the biochemical mechanism 
by which genotoxic stress modulates hnRNP H alternative splicing.  It has been previously noted 
that hnRNP H responds to stress by regulating other proteins, but no direct connection has yet 
been described regarding its own transcript regulation.  Here, we take the first steps to establish 
the series of events that are required to relay the stress signal to hnRNP H mRNA splicing 
modulation.  Additionally, we aim to explore the possibility of larger splicing networks that 
respond to genotoxic stress using the compounds displayed in Figure 1. 
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1. (I) Cisplatin, cis-diamminedichloroplatinum(II), is a chemotherapeutic agent that induces
DNA damage by forming inter- and intra-strand DNA alkyl-like adducts, binding
preferentially to the N7 position of guanines
2. (II) Dichloro(ethylenediamine)platinum (II), and (III) cis-Dichlorobis(pyridine)platinum
(II) are chemical analogs of cisplatin but do not introduce DNA damage
3. (IV) Doxorubicin hydrochloride is another chemotherapeutic agent that has an unrelated
structure and mechanism of action – DNA intercalation
(I) (II)
(III) (IV)
Figure 1. Cisplatin, its analogs, and the unrelated doxorubicin hydrochloride 
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2.0  RESULTS 
2.1 HUMAN HNRNP H PARALOGS ARE HIGHLY CONSERVED IN TWO EXONS 
According to the most recent release of the Ensembl genome browser, the human genome 
contains three genuine (i.e., not pseudogenes) hnRNP H paralogs: hnRNP H1, H2, and H3 
(Flicek 2013).  hnRNP H1 and H3 are multi-exon genes, with 49 and 11 splice variants reported, 
respectively.  (Though hnRNP H2 is listed as having containing two exons, the first exon 
contains only a very small portion of 5’ UTR.  Additionally, there is only one splice variant, 
meaning this small exon is constitutively included in the mature transcript along with the 
remainder of the second exon.)  Notably, the database shows that the canonical forms of H1 and 
H3 contain unusually similar exons both in length (139 bp) and sequence (90.6%): hnRNP H1 
Exon 4 (H1 E4) and hnRNP H3 Exon 3 (H3 E3) (Figure 2).  Besides containing a high degree of 
amino acid similarity, it is also possible that the high level of sequence homology codes for 
similar splicing regulatory elements (ESSs or ESEs).  It is also of note that the intronic regions 
immediately upstream and downstream of the paralagous exons are highly similar, and they also 
have the potential to contain important splicing regulatory elements (ISSs or ESEs) (House 
2008).  Important for splicing regulation, it was previously posited that the skipping of these 
exons might create a frameshift leading to nonsense mediated decay (Grabowski 2004).  The 
possibility for this set of regulatory factors in combination makes hnRNP H especially 
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interesting in light of its previously described role in the splicing of several important cancer-
associated genes. 
Figure 2. Human hnRNP H Paralogs are alternatively spliced 
A) Two paralagous pre-mRNAs of human hnRNP H – H3 and H1 – are alternatively spliced as
cassettes in exons 3 and 4, respectively; positions for primers used in PCR are indicated by 
arrows above the flanking exons 
B) Sequence alignment of hnRNP H3 exon 3 and hnNRP H1 exon 4 by Clustal Omega.  Exonic
bases are in capital letters, while intronic bases are lowercase.  Homology analysis by LALIGN 
reveals 90.6% sequence homology in the exon, 90.0% homology in the final 10 nucleotides of 
the upstream intron, and 83.3% similarity in the first 21 nucleotides of the downstream intron. 
Positions with identical nucleotides are indicated by an asterisk (*) below the alignment 
12 
2.2 HNRNP H3 EXON 3 IS DIFFERENTIALLY SPLICED IN RESPONSE TO 
CISPLATIN IN MOUSE NEUROBLASTOMA CELLS 
In our initial experiments, we tested the effects of cisplatin on hnRNP H3 Exon 3 (H3 E3), in the 
mouse neuroblastoma cell line N18TG2.  Optimization experiments were performed in order to 
obtain a proper dose and time course for drug treatment.  Because of the cytotoxic nature of 
cisplatin, an excess dose would lead to massive cell damage via apoptosis, making RNA 
quantification and subsequent results difficult to interpret.  On the other hand, a small dose could 
potentially render splicing effects negligible due to an insufficient amount entering cells or 
inactivation of cisplatin by endogenous nucleophiles (Sidik 2003).   
Exon-specific PCR primers were used to quantify the ratio of exon inclusion to exclusion 
(Figure 2A, arrows above splicing schematics).  Several optimization reactions revealed that 15 
μM cisplatin applied for 9 hours was sufficient to cause a splicing shift in hnRNP H3 Exon 3. 
Notably, the effect was dose-dependent and time dependent, as longer time courses using higher 
cisplatin doses caused a larger exclusion in Exon 3.  The extent of splicing change is reported as 
a change in Ψ-value (PSI, or “Percent-Spliced-In”), calculated by subtracting the percent exon 
inclusion without treatment from the percent exon inclusion post-treatment (i.e., ΔΨ) (Wang 
2008).  That is, a more negative Ψ is indicative of more exon skipping.  Experiments were 
performed in biological triplicate, and were used to calculate standard deviation (shown as error 
bars) and statistical significance (Student’s t-test, where p<0.05 is significant).   
Though the longer time point showed a more significant change in Exon 3 inclusion 
compared to the shorter experiments (Ψ = -11.6% versus -14.7%), a greater degree of cell death 
was observed for this extended period of time.  Therefore, it was decided that future tests would 
utilize a cisplatin treatment of 9 hours. 
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Figure 3. Optimization of cisplatin treatment in N18TG2, mouse neuroblastoma cells 
A) Agarose gel electrophoresis of PCR products using hnRNP H3 Exon 3-specific primers
reveals bands corresponding to transcripts including and excluding the cassette exon 
B) hnRNP H3 Exon 3 is skipped in a dose-dependent and time-dependent manner upon cisplatin
treatment 
In order to rule out the possibility that cisplatin causes wide-scale changes in multiple 
cellular processes, we probed two features that could lead to confounding results and difficult 
interpretation of later experiments.  First, we performed Western Blots on HeLa 2CCL whole 
cell lysates and immunoblotted for phosphorylated γH2A.X, a species formed at points of DNA 
damage.  We observed a large increase in γH2A.X in cisplatin-treated HeLa cells, whereas cells 
treated with one of the inert platinum-based compounds did not display this dramatic increase 
(Figure 4A).  To determine whether or not cisplatin causes alternative splicing changes in all 
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cellular transcripts, we assayed the splicing pattern of an exon unrelated to hnRNP H, MEN1 
Exon 8.  When HeLa 2CCL cells were subjected to 24 hour cisplatin treatments of 0, 15, and 30 
µM, we observed no significant change in included:skipped ratios (Figure 4B).  This helped to 
show that the splicing effects observed in this study stemming from cisplatin treatment are likely 
due to a specific response rather than a general misregulation of splicing. 
A) Cisplatin causes a large dose-dependent increase in γH2A.X protein levels in vivo in HeLa
cells, indicative of DNA damage.  The two control compounds, DEP and DPP, do not show the 
same large increases in γH2A.X, and have consistently low levels over the three doses 
B) 24 hour cisplatin treatment does not cause significant splicing changes in MEN1 Exon 8
splicing.  This data in conjunction with data from Figure 3 demonstrates that only specific 
transcripts react to cisplatin treatment in HeLa cells 
Figure 4. Cisplatin specificity for DNA damage and splicing in HeLa 2CCL 
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2.3 CISPLATIN CAUSES DOSE-DEPENDENT SKIPPING OF HNRNP H3 EXON 3 
IN HUMAN CELLS 
In order to further validate the splicing changes observed in mouse cells, we repeated the 
previously described experiments using human cervical cancer cells, HeLa 2CCL (ATCC). 
After 9 hours of treatment by 20 or 40 μM cisplatin, similar trends in hnRNP H3 Exon 3 splicing 
were observed, though the effect was more mild than in neuroblastoma cells (Figure 5A).  That 
is, increasing cisplatin doses caused a decrease in H3 E3 inclusion (ΔΨ = -8.4% for the highest 
dose).  It should be noted that the inclusion of H3 E3 was significantly lower in mice in the 
untreated condition than in human cells (approximately 74% versus 95%).  These differences in 
PSI values are likely explained by the tissue-specific nature of alternative splicing patterns, 
which has been well documented (Xu, Modrek, and Lee 2002).  However, species-specific 
effects on splicing cannot be ruled out. 
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 Figure 5. Dose-dependent exon skipping of hnRNP H3 Exon 3 in HeLa 2CCL 
A) After 9 hours of treatment with cisplatin, hnRNP H3 Exon 3 skipping increased by 4.8% and 
8.4% in the lower and higher doses, respectively; analysis was performed based on biological 
triplicate, and a representative gel is shown 
B) The cisplatin analogue DEP was treated and analyzed as for cisplatin, and no change in 
splicing was observed 
C) The cisplatin analogue DPP was treated and analyzed as for cisplatin, and no change in 
splicing was observed 
D) The structurally unrelated Doxorubicin hydrochloride was used in the doses indicated; no 
changes in splicing were observed 
∆Ψ indicates percent change in exon inclusion from untreated 
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In order to determine whether the shifts in exon inclusion were specific to cisplatin or 
were simply an artifact of sample treatment, we utilized several structural analogs of cisplatin to 
see if these control compounds would produce similar or contrasting results.  Two biochemically 
inert platinum-based cisplatin analogs, dichloro(ethylenediamine)platinum(II) (DEP) and (III) 
cis-dichlorobis(pyridine)platinum(II) (DPP), were applied using treatment conditions identical to 
the samples in Figure 5A.  As shown in Figure 5B and 5C, neither compound produced 
significant decreases in exon inclusion, and in some cases resulted in small, insignificant 
increases in hnRNP H3 Exon 3 inclusion.  Similarly, a structurally distinct yet biochemically 
active chemotherapeutic drug, doxorubicin hydrochloride (DOXO), was used as another control 
to determine whether the observed changes in H3 Exon 3 splicing is generalized to all stressors 
or specific to cisplatin-induced genotoxic stress.  Doxorubicin is a DNA intercalating agent and 
therefore interferes with DNA and RNA synthesis (Momparler 1976).  Unlike cisplatin, no 
change in H3 E3 splicing was caused by DOXO, demonstrating the specificity of this effect to 
cisplatin (Figure 5D).  As in the neuroblastoma experiments, all procedures were performed in 
biological triplicate and subjected to the Student’s t-test (i.e., p<0.05 is significant). 
2.4 HNRNP H3 EXON 3 AND HNRNP H1 EXON 4 ARE SPLICED DIFFERENTLY 
IN RESPONSE TO CISPLATIN 
As mentioned previously, hnRNP H has three paralogs in humans, two of which share a 
homologous exon: hnRNP H1 Exon 4 and hnRNP H3 Exon 3.  With such a high degree of 
sequence homology (90.6%), one would expect to observe similar splicing patterns between the 
two exons.  In order to confirm this suspicion, we used PCR primers specific to H1 E4 to 
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compare the level of exon inclusion in the presence of cisplatin relative to H3 E3’s.  
Surprisingly, H1 E4 was significantly more sensitive to cisplatin treatment than H3 E3 (ΔΨ =       
-16.7% versus -8.4%, respectively) (Figure 6A).  The differential regulation of exon inclusion 
could come from a variety of sources, and an attractive hypothesis contributes this observation to 
differences in regulatory cis-acting RNA elements such as E/ISSs and E/ISEs.   
 
 
Figure 6. hnRNP H1 Exon 4 displays increased sensitivity to cisplatin treatment in HeLa 
A) Inclusion of hnRNP H1 Exon 4 decreased significantly in both cisplatin treatments, and 
both were more dramatic than the response of hnRNP H1 Exon 3 
B) H3 E3 and H1 E4 vary in putative binding sites for possibly relevant splicing factors, 
including hnRNP H; putative hnRNP H sites are shown in blue, SC35 in red, and hnRNP 
A1 in orange (where overlapping sites exist, colored underlines are shown) 
 
In order to explore this possibility, the two exons in question were aligned using 
ClustalW, including intronic regions immediately upstream and downstream of the splice sites.  
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Each sequence was applied to bioinformatics programs that predict regulatory motifs for several 
splicing factors (Human Splicing Factor 2.4.1, Desmet 2009; SFmap 1.8, Paz 2010, Akerman 
2009).  The RNA maps produced for each revealed a great deal of similarity, though a few 
important differences were seen.  For example, H3 E3 contains one exonic and three intronic 
putative hnRNP H binding sites not found in H1 E4.  Additionally, H3 E3 contains an extended 
hnRNP A1 RNA element compared to H1 E4 and an unshared SC35 site.  On the other hand, H1 
E4 contains two exonic hnRNP H binding sites not found in H3 E3 in addition to a unique 
hnRNP A1 site.  Because RNA binding proteins (such as splicing factors) are often 
autoregulatory (Buratti 2011), and the two exons show several dissimilarities in hnRNP H 
binding sites, we hypothesized that the differences in regulatory motifs may help to explain the 
significantly different splicing changes in addition to hnRNP H’s response to cisplatin. 
2.5 HNRNP H BINDS TO ITS OWN MRNA 
Before exploring the role of individual regulator motifs on hnRNP H’s autoregulation, we first 
sought to confirm that H in fact interacts with its own transcript in the exon described.  To test 
this, an electrophoretic mobility shift assay (EMSA) was performed, using recombinant hnRNP 
H protein and fluorescently labeled hnRNP H1 E4 RNA transcript.  Because RNA-protein 
complexes are heavier than RNA or protein alone, interactions between hnRNP H and its mRNA 
would be expected to reduce the mobility of RNA in a polyacrylamide gel.  This effect was 
indeed observed, as RNA migrated significantly faster in a native gel compared with RNA plus 
protein mixtures.  This interaction was further confirmed by the fact that increasing amounts of 
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protein created a more significant upward shift in mobility relative to a sample with half the 
concentration of protein.   
In order to determine the sequence specificity of this interaction, in vitro binding assays 
with competitor oligonucleotides will need to be performed.  If the interaction were truly specific 
for any or all of the putative sites, competitor sequences would reduce the protein’s interactions 
with the labeled probe, binding to the unlabeled molecule instead.  However, if this binding is 
unspecific and is a more general RNA-protein interaction, competitor oligo would compete for 
binding less effectively.  Additionally, it would be important to determine where exactly on the 
exon hnRNP H binds, especially to determine the effects of nucleotide sequence within codons 
(as discussed above).  
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An electrophoretic mobility shift assay shows that recombinant hnRNP H causes an upward 
mobility shift when incubated with RNA encoding hnRNP H1 Exon 4.  Control lane 1 containing 
only protein does no fluoresce because it does not contain labeled UTP.  Control lane 2 shows 
basal mobility of the H1 E4 transcript in the polyacrylamide gel. 
Figure 7. Recombinant hnRNP H binds to its own in vitro synthesized transcript 
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3.0  DISCUSSION 
 
 
 
 
Since its discovery approximately 40 years ago, alternative RNA splicing and its regulation have 
been studied extensively.  It has more recently been discovered that aberrant alternative RNA 
splicing can be attributed to causing several – if not many – human diseases that span a range of 
organ systems over varying developmental time (Faustino 2003; Wang 2007; Poulos 2011).  
Perhaps unsurprisingly, it has also come to light that many instances of cancer – a disease 
associated with high mutational loads and genomic instability – are either caused by, sustained 
by, or lead to aberrant alternative splicing (Venables 2004; David 2010; Sette 2013; Ladomery 
2013).    
In light of new sequencing technologies, advances in bioinformatics, and improved 
methods for large-scale analyses of alternative splicing decisions, many interesting patterns in 
the relationship between splicing and disease have emerged (Lee 2005).  For example, Wang and 
colleagues demonstrated on an exome-wide scale that members of the hnRNP H/F family of 
splicing regulators can both modulate exon inclusion and exclusion in a context-dependent 
manner through several modes of alternative splicing (e.g., cassette exons, alternative 5’/3’ splice 
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sites, etc.).  Functionally, the authors demonstrated a global link to a developmental shift from 
oligodendrocyte progenitor cells to oligodendrocytes (Wang 2012).  This study exemplifies a 
marked shift from previous studies addressing a single exon, single gene, or single pathway 
(Gonçalves 2009, for example).   
Despite this recent glut of genome-wide, exome-wide, and transcriptome-wide 
information, there is strikingly little reporting on comprehensive splicing pathways or programs 
from this data.  One of the most important and well-understood examples of such a program 
involves two isoforms of pyruvate kinase M (PKM): PKM1 and PKM2. PKM1 is expressed in 
normal cells, while PKM2 is preferentially selected in cancer cells due to its shift toward 
anaerobic respiration.  The difference between these isoforms is as simple as the exchange of one 
mutually exclusive exon for another, facilitated at least partially by hnRNPs A1, A2, and I (or 
PTB) (Christofk 2008; Chen 2010).  Several other studies approach similar phenomena with 
more global perspectives generalizable either to certain types of cancers or cancer in general.  
Such projects often identify families of splicing factors, cis-acting regulatory elements, or modes 
of splicing events that are differentially regulated in cancers such as SRSF proteins, FOX 
proteins, and hnRNPs (Bradmard 2009; Lapuk 2010; Shapiro 2011).  While each of these reports 
approaches alternative splicing regulation from a relatively large-scale view, they mention 
several specific mechanisms by which each splicing switch works. 
Another gap in the literature that the current study aims to fill is in understanding how 
splicing programs interact with environmental cues besides tumorigenic effects.  Many reports 
demonstrate how specific splicing factors either alter or are altered by diseased states, but do not 
consider the dynamic nature of alternative splicing with respect to integration of spatiotemporal 
and chemical signals.  Here we have demonstrated an exon-specific and signal-specific reaction 
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of cancer cells to genotoxic stress.  Our findings show that homologous exons from two human 
paralogs of hnRNP H, H1 E4 and H3 E3, react to treatment with cisplatin via a dose-dependent 
exclusion of the exon.  This reaction was likely dependent on the presence of genotoxic stress in 
the form of alklyation, as neither inert control compounds nor a DNA intercalating agent elicited 
this effect.  Additionally, hnRNP H1 Exon 4 is more sensitive to cisplatin treatment, as it 
experiences a more significant decrease in inclusion as a result of identical drug dosages.  A map 
of cis-acting regulatory elements within these exons and the immediately adjacent intronic 
regions suggest possible mechanisms both for this effect in general in addition to the basis for H1 
E4’s heightened reaction to cisplatin.  Though the exact pathway that transduces the signal from 
cisplatin to hnRNP H1 and H3 splicing shifts has yet to be elucidated, the observation that 
hnRNP H binds to this exon with moderate affinity suggests a possible autoregulatory feedback 
loop.  This type of autoregulation is certainly precedented, and can be found in the 
autoregulation of other splicing factors such as SRSF1 mRNA stability by NMD, SC35 mRNA 
by alternative splicing in the 3’ UTR, and other RNA-binding proteins (Sun 2010; Sureau 2001; 
Brenner 2007; Wollerton 2007). 
Though the splicing shifts of H1 E4 and H3 E3 were observed throughout numerous 
experiments, both in data shown and not shown, it is arguable that the extent of exclusion for 
these exons is rather small compared to similar systems.  For example, SRSF1 mRNA 
experiences up to a 30% decrease in exon inclusion in response to autoregulation compared to a 
maximal value of 16% in this study.  However, the cytotoxic effects of cisplatin were the 
ultimately limiting factors in this study: while much higher doses of cisplatin may have produced 
a larger modulation in H1 E3 and H3 E3 exon exclusion, they almost certainly would have led to 
massive cell death and degradation of RNAs of interest.  Additionally, we believe that the 
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reproducibility of experiments utilizing the two control platinum-based compounds DEP and 
DPP further validates our observations to a level sufficient to support our conclusions.  We hope 
to conduct further experiments that demonstrate the specificity of this effect not only to cisplatin, 
but to exons regulated by hnRNP H.  In showing this, we would have more evidence for an 
autoregulatory mechanism of action in cisplatin-induced reactions. 
While we have collected data suggesting the beginnings of a larger splicing program, 
genome-wide and transcriptome-wide studies need to be performed before drawing larger 
conclusions about cisplatin’s effects on hnRNP H and splicing in general.  In line with this 
thinking, a 2012 proteomic study by Zhang and colleagues suggested that cisplatin causes an 
upregulation in nuclear hnRNP H, though the methods used do not make this obvious (Zhang 
2012).  In utilizing conventional wisdom about hnRNPs, this presents possibly counterintuitive 
logic.  Specifically, hnRNPs are typically considered to repress exon inclusion; if hnRNP H 
regulates the inclusion of H1 or H3, increasing nuclear concentration of the protein would create 
a larger exclusion of the exon, in line with the data presented in this study.  However, because of 
the premature termination codon transcribed when these exons are excluded, one would expect 
nuclear concentrations of hnRNP H to decrease through the nonsense mediated decay (NMD) 
pathway.  These seemingly paradoxical conclusions need to be explored further, and will come 
with further analysis of hnRNP H’s reaction to cisplatin and possible contributions from NMD. 
The goals of this thesis originally presented were partially fulfilled, and require further 
work.  The basis for a possible autoregulatory loop in hnRNP H splicing has been established 
through assays involving stressors.  While genome-wide studies have become increasingly 
important, especially in light of so-called splicing networks, several preliminary steps must be 
completed before grander correlations can be explored.  Direct evidence of hnRNP H’s binding 
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occupancy on its own transcript in several stressful contexts will be an important step in bridging 
this gap.  Additionally, the biochemical connection between DNA damage and hnRNP H 
splicing changes will need to be explored in order to predict other upstream and downstream 
consequences of these changes. 
Though this study only fills a very small gap in the data about environmental reactions to 
stress through splicing mechanisms, it begins to approach a rather profound question regarding 
cellular decision making: How is the sum of all cues, internal and external, chemical and 
physical, spatial and temporal, processed by biomolecules, and how does this converge on 
alternative splicing?  As small pieces of questions like these are answered, we can not only begin 
to understand how biology of normal cells works, but how diseased states change this 
homeostasis and how we can return it to a healthy condition.   
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4.0  MATERIALS AND METHODS 
4.1 PRIMER SEQUENCES 
Table 1. List of Primers Used 
Primer Name Sequence Organism (Cell Line) 
H3_E3_F 5’-AAT GGT CCA AAT GAC GCT AG-3’ Mouse (N18TG2), Human 
(HeLa 2CCL) 
H3_E3_R 5’-CCA GCA ATC TTC TTG GTG G-3’ Mouse (N18TG2), Human 
(HeLa 2CCL) 
hH1_E4_F 5’-TTG GGT GTT GAA GCA TAC TGG-3’ Human (HeLa 2CCL) 
hH1_E4_R 5’-CAT AAG CTT TCG TCG TGG ATC A-3’ Human (HeLa 2CCL) 
 
4.2 HELA CELLS, CISPLATIN TREATMENT, AND RNA ANALYSIS 
HeLa 2CCL (ATCC) cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum and grown in a sterile 
tissue culture incubator at 370C with 5% atmospheric CO2.  Drug treatments were performed in 
6-well plates once cells reached 60% to 90% confluence.  Cisplatin stock solutions were 
prepared fresh from powder using 0.9% NaCl in ddH2O as the solvent.  Stock solutions were 
added to DMEM + 10% FBS immediately before treatments to produce the desired final 
 28 
experimental dosage (20 μM or 40 μM) for 9 hours.  Mock treatments without cisplatin were 
performed in parallel.  Control drug treatments were performed using 
dichloro(ethylenediamine)platinum(II) (DEP), cis-Dichloro(dipyridine)platinum(II) (DPP), and 
doxorubicin.  Control drug treatments were performed in identical conditions and concentrations 
as cisplatin, except for doxorubicin, for which we used 0 μM (mock), 1.5 μM, and 3 μM doses 
for 9 hours.  Total RNA was collected by pooling identical treatments and using TRIzol 
according to the manufacturer’s instructions.  RNA concentrations were measured using A260 
spectrophotometry.  cDNA was synthesized from RNA using random primers and SuperScript 
III reverse transcriptase.  Exon inclusion/exclusion data was obtained by performing PCR on 
cDNA using primers flanking the exon being quantified.  PCR products were run on agarose gels 
and bands were detected using EtBr staining.  ImageGauge software was used to quantify band 
intensity and ratios were taken to calculate the percentage of exon inclusion:exclusion in each 
treatment.  
4.3 WHOLE CELL LYSATE PREPARATION, SDS-PAGE AND WESTERN 
BLOTTING 
SDS-PAGE and Western Blotting protocols were performed similarly to Dembowski 2009.  
HeLa 2CCL cells were grown and treated as described above.  Whole cell lysates were obtained 
by decanting cell media prior to extraction followed by treatment with RIPA buffer 
(supplemented with protease inhibitor cocktail and phosphatase inhibitor in the form of sodium 
orthovanadate).  After incubating for at least 10 minutes in a cold room, lysates were transferred 
to Eppendorf tubes and subjected to sonification, three times per sample for 10 seconds per 
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round, making sure to return to ice after each pulse.  Cellular debris was removed by 
centrifugation, and the supernatant was flash frozen until ready for use. 
Samples were treated with SDS, boiled, mixed with running buffer, and loaded onto a 
polyacrylamide gel for electrophoresis-mediated protein separation.  After the bromophenol blue 
band ran to the bottom of the gel, a wet blotting procedure was performed to transfer the contents 
of the gel to a PVDF membrane.  After electrophoretic transfer, the membrane was blocked in 
milk, washed in PBST, and incubated in the primary monoclonal antibody indicated in Figure 4.  
After incubation for one hour, membranes were washed in PBST four times each for 10 minutes 
per wash.  Membranes were next incubated in polyclonal secondary antibody conjugated to 
horseradish peroxidase for one hour.  Following the same washing procedure as followed 
primary antibody incubation, membranes were treated with Western Blotting detection solutions 
as per the manufacturer’s instructions.  Proteins were detected via chemiluminescence imaging 
over several time points to obtain images with optimal signal:background ratios. 
4.4 IN VITRO TRANSCRIPTION 
pIDT_H1E4 plasmid was transformed into DH5α E. coli and extracted using QIAprep Spin 
Miniprep Columns (Qiagen).  25 μg purified DNA was restriction digested in 10 μL EcoRI 
(NEB) and EcoRI Buffer (NEB) in a reaction volume of 200 μL.  The reaction was carried out 
for 3-4 hours at 370C followed by a 20 minute heat killing stage at 650C.  Complete digestion 
was confirmed using a 0.8% agarose gel stained with EtBr.  Both supercoiled and nicked bands 
were detectable in the uncut control lane, while only a linearized band was seen in the digested 
sample.  Digested DNA was purified by buffered phenol-chloroform extraction followed by 
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ethanol precipitation.  0.75-1 μg pure DNA was used for each transcription reaction, in addition 
to 500 μM each NTP (UTP, ATP, GTP, CTP), 1x Transcription Buffer, and T3 RNA Polymerase 
(Ambion) in a total volume of 20 μL.  The reaction was carried out for one hour at room 
temperature for unlabeled transcripts and two hours at 370C for fluorescently labeled samples.  1 
μL TURBO DNase (Ambion) and 1 μg 0.5 M EDTA were added and incubated at 370C for 15 
minutes to stop the reaction and to degrade DNA.  Unincorporated nucleotides were removed 
using NucAway Spin Columns (Ambion).  Remaining protein contaminants were removed by 
ethanol precipitation using 2 volumes 100% ethanol and 1/10 volume 3 M sodium acetate, pH 
5.2.  RNA was resuspended in 25-30 μL ddH2O to give concentrations of between 61 and 150 
ng/μL. 
For fluorescently labeled probes, an identical procedure was performed, except 750 ng 
template DNA was used and instead of running the transcription reaction with 0.5 mM unlabeled 
UTP, ChromaTide Alexa Flour 488-5-UTP (Life Technologies) was combined with unlabeled 
UTP at a ratio that gave quantifiable labeling of RNA molecules without inhibiting T3 
polymerase activity.   
4.5 ELECTROPHORETIC MOBILITY SHIFT ASSAYS 
The protocol for electrophoretic mobility shift assays was modified from Dembowski 
2009.  Secondary structures in the RNA transcript were removed by heating an aliquot to 850C 
for 5 minutes and cooling to 370C for 5 minutes.  Protein-containing samples were prepared on 
ice in binding buffer (50 mM Tris pH8.0, 150 mM NaCl, 0.1 mg/ml tRNA, 2 mM DTT), and 
then heated to 370C for 5 minutes.  After incubating the RNA and protein samples separately for 
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the indicated times, appropriate amounts of RNA were added to the protein-buffer mixtures.  All 
samples were prepared to a final volume of 25 μL.  The samples were allowed to incubate on ice 
for 1 hour, followed by the addition of 2 μL native loading dye (50% glycerol, 0.1% xylene 
cyanol, 0.1% bromphenol blue). After 5 minutes of pre-running a TBE-buffered 6% 
polyacrylamide (80 acrylamide : 1 bisacrylamide ratio) gel at 120V in a cold room, 13 μL of 
each sample were loaded onto gel.  To align samples in the wells, 180V was applied to the gel 
for 5 minutes, followed by a 1 hour run at 120V.  Reactions were kept out of light and were 
imaged using a 473 nm laser at 400V. 
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